UNLABELLED: Our purpose was to assess the impact of a secondary prevention program for osteoporotic fractures in patients with fragility fracture and to determine its effect on long-term compliance with bisphosphonate treatment. Persistence with bisphosphonate use was 71%. Attending follow-up visits was the only variable significantly associated with adherence to bisphosphonates. INTRODUCTION: The aim of this study is to assess the impact a secondary prevention program for osteoporotic fractures in a prospective cohort of patients with at least one fragility fracture and to determine the effect of this intervention on long-term compliance with bisphosphonate treatment. METHODS: All patients older than 50 years with a fragility fracture attended at the emergency department over a 2-year period were appointed for a clinical visit through a telephone call. Two follow-up controls at 4 and 12 months were scheduled. After a mean of 4 years, a telephone survey was conducted to assess compliance with treatment. RESULTS: Of 683 eligible patients, 380 (55.6%) were visited at the hospital. Previous treatment with bisphosphonates was recorded in 17.9% of patients. DXA scan was considered normal in 61 patients and revealed osteopenia in 184 and osteoporosis in 135. Pharmacological treatment was indicated in 90% of patients (alendronate in 76%). Among 241 patients who participated in the survey, eight patients had new fractures (four were on treatment with bisphosphonates and four had discontinued treatment). Of 187 patients in which bisphosphonates were prescribed at the initial visit, 133 (71.1%) continued using bisphosphonates. Attendance of scheduled visits was associated with adherence to bisphosphonates (odds ratio, 3.33; 95% confidence interval, 2.99-3.67). CONCLUSIONS: The efficacy of the program to recruit patients was 55%. In patients visited at the hospital, treatment with bisphosphonates increased from 17.9% to 76%. Persistence with bisphosphonate use after a mean of 4 years was 71%. Attending follow-up visits was significantly associated with adherence to bisphosphonates.
UNLABELLED: Our purpose was to assess the impact of a secondary prevention program for osteoporotic fractures in patients with fragility fracture and to determine its effect on long-term compliance with bisphosphonate treatment. Persistence with bisphosphonate use was 71%. Attending follow-up visits was the only variable significantly associated with adherence to bisphosphonates. INTRODUCTION: The aim of this study is to assess the impact a secondary prevention program for osteoporotic fractures in a prospective cohort of patients with at least one fragility fracture and to determine the effect of this intervention on long-term compliance with bisphosphonate treatment. METHODS: All patients older than 50 years with a fragility fracture attended at the emergency department over a 2-year period were appointed for a clinical visit through a telephone call. Two follow-up controls at 4 and 12 months were scheduled. After a mean of 4 years, a telephone survey was conducted to assess compliance with treatment. RESULTS: Of 683 eligible patients, 380 (55.6%) were visited at the hospital. Previous treatment with bisphosphonates was recorded in 17.9% of patients. DXA scan was considered normal in 61 patients and revealed osteopenia in 184 and osteoporosis in 135. Pharmacological treatment was indicated in 90% of patients (alendronate in 76%). Among 241 patients who participated in the survey, eight patients had new fractures (four were on treatment with bisphosphonates and four had discontinued treatment). Of 187 patients in which bisphosphonates were prescribed at the initial visit, 133 (71.1%) continued using bisphosphonates. Attendance of scheduled visits was associated with adherence to bisphosphonates (odds ratio, 3.33; 95% confidence interval, 2.99-3.67). CONCLUSIONS: The efficacy of the program to recruit patients was 55%. In patients visited at the hospital, treatment with bisphosphonates increased from 17.9% to 76%. Persistence with bisphosphonate use after a mean of 4 years was 71%. Attending follow-up visits was significantly associated with adherence to bisphosphonates.
Authors: Sumit R Majumdar; Brian H Rowe; Deb Folk; Jeffrey A Johnson; Brian H Holroyd; Donald W Morrish; Walter P Maksymowych; Ivan P Steiner; Charles H Harley; Brian J Wirzba; David A Hanley; Sandra Blitz; Anthony S Russell Journal: Ann Intern Med Date: 2004-09-07 Impact factor: 25.391
Authors: Adrianne Feldstein; Patricia J Elmer; David H Smith; Michael Herson; Eric Orwoll; Chuhe Chen; Mikel Aickin; Martha C Swain Journal: J Am Geriatr Soc Date: 2006-03 Impact factor: 5.562
Authors: A Naranjo; S Ojeda-Bruno; A Bilbao-Cantarero; J C Quevedo-Abeledo; B V Diaz-González; C Rodríguez-Lozano Journal: Osteoporos Int Date: 2015-06-06 Impact factor: 4.507
Authors: M Hiligsmann; M Salas; D A Hughes; E Manias; F H Gwadry-Sridhar; P Linck; W Cowell Journal: Osteoporos Int Date: 2013-05-01 Impact factor: 4.507
Authors: B Mugnier; A Daumas; S Doddoli; S Belmeliani; A-L Couderc; B Mizzi; P Lévêque; P Villani Journal: Osteoporos Int Date: 2020-01-11 Impact factor: 4.507
Authors: D A Eekman; S H van Helden; A M Huisman; H J J Verhaar; I E M Bultink; P P Geusens; P Lips; W F Lems Journal: Osteoporos Int Date: 2013-09-13 Impact factor: 4.507
Authors: Helena Parente Vieira; Ingrid Almeida Leite; Thayga Maria Araújo Sampaio; Juliane Dos Anjos de Paula; Ankilma do Nascimento Andrade; Luiz Carlos de Abreu; Vitor E Valenti; Flavia C Goulart; Fernando Adami Journal: Int Arch Med Date: 2013-05-24